Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are heterogeneous
regarding site of origin, biological behavior, and malignant potential. There has been a rapid …

We introduce and validate a new precision oncology framework for the systematic
prioritization of drugs targeting mechanistic tumor dependencies in individual patients …

Background The lack of an accurate blood biomarker in neuroendocrine tumor (NET)
disease has hindered management. The advance of genomic medicine and the …

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare,
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …

Background Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor
(SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy …

Octreotide and lanreotide are the two somatostatin analogs (SSA) currently available in
clinical practice. They have been approved first to control the clinical syndrome (mainly …

Neuroendocrine neoplasms (NENs) are derived from neuroendocrine cell system and can
have benign or malignant characteristics. They are rare tumors, but have been increasing in …

68Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor–
expressing tumors. Integrating this imaging data effectively in patient care requires the …